Tiny study on drug monitoring in scleroderma ends early
NCT ID NCT04244916
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was terminated, so no meaningful results were obtained. The research was exploratory and did not lead to any clear conclusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mycophenolate mofetil (MMF)
- What this could lead to
- If successful, it could help doctors personalize MMF dosing for better skin and lung outcomes in systemic sclerosis.
- What could go wrong
- The study was terminated early with only 2 participants, so no reliable conclusions can be drawn. The approach may not improve outcomes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin hospital, AP-HP
Paris, France, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts